Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Wuxi Biologics (Cayman) Inc. (HK:2269)
HKEX:2269
Holding HK:2269?
Track your performance easily
2269 Stock Chart & Stats
Day’s RangeHK$0 - HK$0
52-Week RangeHK$10.14 - HK$47.05
Previous CloseHK$14.4
Volume63.64M
Average Volume (3M)84.40M
Market Cap
HK$59.83B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)21.1
Beta1.67
Next Earnings
Mar 25, 2025EPS Estimate
HK$0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.68
Shares OutstandingN/A
10 Day Avg. Volume57,383,950
30 Day Avg. Volume84,396,083
Standard Deviation0.17
R-Squared0.42
Alpha0.00703
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)14.68
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$25.14Price Target Upside74.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Wuxi Biologics (Cayman) News
PremiumCompany Announcements
WuXi Biologics Welcomes New Non-Executive Director
PremiumCompany Announcements
WuXi Biologics Updates Board and Committees
PremiumCompany Announcements
WuXi Biologics Responds to U.S. House Draft BillPremiumCompany Announcements
WuXi Biologics Acquires Full Ownership of WuXi Vaccines
PremiumCompany Announcements
WuXi Biologics Announces 2024 Interim Results Call
PremiumCompany Announcements
Wuxi Biologics Reports Mixed Mid-Year FinancialsBulls Say, Bears Say
Bulls Say
Financial PerformanceAntibody-drug conjugate and commercial deals are expected to provide stable recurring cash flows, as commercial projects generate significantly more revenue than early-stage projects.
Global ExpansionWuXi Biologics has been expanding its services overseas to increase its global footprint, which is preferred by clients.
Market PositionWuXi Bio is a leading biologics research and manufacturing service provider, boasting a 13% global market share and 70% in China.
Bears Say
Business ExposureThe potential approval of the Biosecure Act puts more than 50% of WuXi Biologics' business at risk, as it primarily operates in America.
Market SentimentHeadwinds from the Biosecure Act will persist, causing negative market sentiment and significant share price declines for WuXi Biologics.
Regulatory RisksThe Biosecure Act, if passed, would ban US companies from dealing with WuXi Biologics by 2032, posing a significant threat to the company's business.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
5.80% Mutual Funds
0.02% Other Institutional Investors
87.43% Public Companies and
Individual Investors
2269 FAQ
What was Wuxi Biologics (Cayman) Inc.’s price range in the past 12 months?
Wuxi Biologics (Cayman) Inc. lowest stock price was HK$10.14 and its highest was HK$47.05 in the past 12 months.
What is Wuxi Biologics (Cayman) Inc.’s market cap?
Currently, no data Available
When is Wuxi Biologics (Cayman) Inc.’s upcoming earnings report date?
Wuxi Biologics (Cayman) Inc.’s upcoming earnings report date is Mar 25, 2025 which is in 122 days.
How were Wuxi Biologics (Cayman) Inc.’s earnings last quarter?
Wuxi Biologics (Cayman) Inc. released its earnings results on Aug 21, 2024. The company reported HK$0.376 earnings per share for the quarter, missing the consensus estimate of HK$0.441 by -HK$0.064.
Is Wuxi Biologics (Cayman) Inc. overvalued?
According to Wall Street analysts Wuxi Biologics (Cayman) Inc.’s price is currently Undervalued.
Does Wuxi Biologics (Cayman) Inc. pay dividends?
Wuxi Biologics (Cayman) Inc. does not currently pay dividends.
What is Wuxi Biologics (Cayman) Inc.’s EPS estimate?
Wuxi Biologics (Cayman) Inc.’s EPS estimate is HK$0.43.
How many shares outstanding does Wuxi Biologics (Cayman) Inc. have?
Wuxi Biologics (Cayman) Inc. has 4,155,007,300 shares outstanding.
What happened to Wuxi Biologics (Cayman) Inc.’s price movement after its last earnings report?
Wuxi Biologics (Cayman) Inc. reported an EPS of HK$0.376 in its last earnings report, missing expectations of HK$0.441. Following the earnings report the stock price went down -2.906%.
Which hedge fund is a major shareholder of Wuxi Biologics (Cayman) Inc.?
Among the largest hedge funds holding Wuxi Biologics (Cayman) Inc.’s share is Gilder Gagnon Howe & Co LLC.. It holds Wuxi Biologics (Cayman) Inc.’s shares valued at N/A.
---
Wuxi Biologics (Cayman) Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-69.81%
12-Months-Change
Fundamentals
Return on Equity
6.75%
Trailing 12-Months
Asset Growth
7.57%
Trailing 12-Months
Company Description
Wuxi Biologics (Cayman) Inc.
Wuxi Biologics (Cayman), Inc. is an investment holding company, which engages in the discovery, development and manufacture of biologics services. Its services include testing; clinical drug substance cGMP manufacture; commercial drug substance cGMP manufacture; drug product cGMP fill and finish; antibody drug conjugates; regulatory affairs; and technologies and platforms. The company was founded on May 24, 2010 and is headquartered in Wuxi, China.
---
2269 Company Deck
---
2269 Earnings Call
Q2 2024
0:00 / 0:00
---
2269 Stock 12 Month Forecast
Average Price Target
HK$25.14
▲(74.56% Upside)
Technical Analysis
Best Analysts Covering 2269
1 Year
1 Year Success Rate
2/4 ratings generated profit
1 Year Average Return
+0.65%
reiterated a buy rating 3 months ago
Copying Jialin Zhang's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +0.65% per trade.
---